• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Colon Carcinoma - Pipeline Review, H1 2013 Product Image

Colon Carcinoma - Pipeline Review, H1 2013

  • ID: 2517896
  • March 2013
  • 43 pages
  • Global Markets Direct

Colon Carcinoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Colon Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Colon Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Carcinoma. Colon Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Colon Carcinoma.
- A review of the Colon Carcinoma products under development by companies and universities/research institutes based READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Colon Carcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Colon Carcinoma 7
Colon Carcinoma Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Discovery and Pre-Clinical Stage Products 12
Comparative Analysis 12
Colon Carcinoma Therapeutics – Products under Development by Companies 13
Companies Involved in Colon Carcinoma Therapeutics Development 14
Eli Lilly and Company 14
Glycotope GmbH 15
German Cancer Research Center 16
AIMM Therapeutics B.V. 17
PepTx, Inc. 18
DEKK-TEC, Inc. 19
Colon Carcinoma – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
cetuximab - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BACPT DP - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
KaroMab-GEX - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PTX-001 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
P-900 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
P-732 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PTX-004 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antibodies For Gastrointestinal Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Colon Carcinoma Therapeutics – Drug Profile Updates 39
Colon Carcinoma Therapeutics – Discontinued Products 40
Colon Carcinoma Therapeutics - Dormant Products 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products Under Development for Colon Carcinoma, H1 2013 7
Products under Development for Colon Carcinoma – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Eli Lilly and Company, H1 2013 14
Glycotope GmbH, H1 2013 15
German Cancer Research Center, H1 2013 16
AIMM Therapeutics B.V., H1 2013 17
PepTx, Inc., H1 2013 18
DEKK-TEC, Inc., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Colon Carcinoma Therapeutics – Drug Profile Updates 39
Colon Carcinoma Therapeutics – Discontinued Products 40
Colon Carcinoma Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Colon Carcinoma, H1 2013 7
Products under Development for Colon Carcinoma – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Discovery and Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos